Last updated: February 27, 2026
What Is NDC 72578-0106?
NDC 72578-0106 is a drug marketed by ChemoCentryx Inc., identified as Tavneos (avacopan) in treatment applications. It is an oral, small-molecule complement component 5a (C5a) receptor inhibitor approved by the FDA for active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Market Landscape
Indication and Patient Population
- Target disease: ANCA-associated vasculitis, a rare autoimmune disorder
- Prevalence: Estimated 3 per 100,000 individuals globally, with variations across regions
- Market potential: Limited to specialized centers; high unmet medical need due to the immunosuppressive burden of existing therapies
Competitive Environment
| Drug Name |
Mechanism |
Marketed By |
Approval Date |
Annual Sales (2022) |
Key Competitors |
| Rituximab (Rituxan) |
Anti-CD20 monoclonal antibody |
Genentech/Biogen |
2011 (for vasculitis) |
$3.6 billion |
Cyclophosphamide, azathioprine |
| Cyclophosphamide |
Alkylating agent |
Multiple manufacturers |
Approved long ago |
N/A |
Rituximab, avacopan |
| Avacopan (NDC 72578-0106) |
C5a receptor inhibitor |
ChemoCentryx Inc. |
October 2021 |
Not yet established |
Rituximab, plasma exchange |
Regulatory and Reimbursement Status
- FDA approval: October 2021 for AAV
- Pricing: Orphan drug designation affirms higher prices; premium pricing is anticipated
- Reimbursement considerations: Coverage likely aligned with specialty pharmacy channels; insurers may prefer lower-cost alternatives unless clinical benefits justify premiums
Price Projections
Current Price Positioning
- Initial wholesale acquisition cost (WAC): Estimated at approximately $60,000 - $70,000 per year per patient
- Comparison to competitors: Rituximab infusion therapy averages $25,000 - $40,000 per treatment course; modest premium likely justified by oral administration and safety profile
Forward-Looking Price Trends
| Year |
Price Range (WAC, per patient/year) |
Key Factors |
| 2023 |
$65,000 - $75,000 |
Initial adoption, limited coverage, premium positioning |
| 2024 |
$60,000 - $70,000 |
Negotiations with payers, market expansion |
| 2025+ |
$55,000 - $65,000 |
Increased competition, generic or biosimilar entry possible |
Revenue Projections
Assuming a conservative market penetration:
| Year |
Estimated Patients |
Annual Revenue |
Notes |
| 2023 |
1,000 - 2,000 |
$65M - $150M |
Early market share, premium pricing |
| 2024 |
2,500 - 4,000 |
$150M - $280M |
Expanded access and reimbursement gains |
| 2025 |
4,500 - 7,000 |
$250M - $455M |
Broader adoption in treatment protocols |
Risks and Limitations
- Competitive price pressure from established therapies
- Payer restrictions due to orphan drug exclusivity
- Long-term safety profile under real-world conditions unknown
Key Takeaways
- NDC 72578-0106 (avacopan) entered the AAV treatment market in 2021 with a premium price position.
- Market penetration remains moderate, constrained by small patient population and reimbursement dynamics.
- Price projections suggest decreasing WAC over time, influenced by competition and negotiations.
- Peak revenues estimated at approximately $250M–$455M annually by 2025, contingent on adoption and clinical outcomes.
- Market risks include payer restrictions, competition, and potential biosimilar or generic patent challenges.
FAQs
Q1: How does avacopan compare to existing AAV treatments?
It offers an oral alternative to infusion therapies like rituximab, with a potentially better safety profile and convenience, but at a higher price point.
Q2: What factors could influence the drug's future price?
Market competition, clinical trial results, payer negotiations, and broader adoption strategies.
Q3: Is the market for NDC 72578-0106 expected to grow?
Yes, as awareness increases and approval for additional indications potentially expands, but growth remains limited by the small patient population.
Q4: What are the main barriers to higher revenue?
Reimbursement constraints, clinician familiarity, competition from established therapies, and the small disease prevalence.
Q5: Are biosimilars or generics expected?
Not likely in the near term due to orphan drug status and patent protections; biosimilar entry might occur after patent expiry.
References
- Food and Drug Administration. (2021). FDA approves Tavneos for treatment of ANCA-associated vasculitis. [Online].
- IQVIA. (2022). Global Prescription Drug Sales Data.
- ChemoCentryx Inc. Financial Reports. (2022).
- U.S. Census Bureau. (2020). Rare Disease Patient Estimates.
[1] Food and Drug Administration. (2021). FDA approves Tavneos for treatment of ANCA-associated vasculitis.
[2] IQVIA. (2022). Global Prescription Drug Sales Data.
[3] ChemoCentryx Inc. Financial Reports. (2022).
[4] U.S. Census Bureau. (2020). Rare Disease Patient Estimates.
